Gene therapy upstart recruits more ex-AveXis talent; I-Mab reveals first-half results
It hasn’t been hard to see where Sean Nolan went looking for the talent needed to make Taysha into a leading player in the bustling gene therapy field.
Monday morning the company, where Nolan holds the chairman’s post, put out word that Taysha recruited the ex-CMO and ex-CFO at AveXis to come onto the board in the wake of a $94 million crossover raise.
In this environment, it’s yet another sign that Nolan and the top crew could have their sights set on an IPO as the biotech upstart completes the full team.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters